Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Aging (Albany NY) ; 6(3): 207-14, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24704640

RESUMO

Hyperglycemia impairs insulin secretion as well as insulin action, being recognized as the glucotoxicity that accelerates diabetes. However, the mechanism underlying the glucotoxicity in pancreatic ß-cells is not thoroughly understood. Hyperglycemia alters glucose metabolism within ß-cells and interstitial conditions around ß-cells, including elevated osmolarity and increased concentrations of insulin and ATP released from overstimulated ß-cells. In this study, to explore direct effects of these alterations on ß-cells, single ß-cells isolated from rat islets were cultured for 3 days with high (22.3 mM) glucose (HG), compared with control 5.6 mM glucose, followed by their functional assessment by measuring cytosolic Ca2+ concentration ([Ca2+]i). The [Ca2+]i response to a physiological rise in glucose concentration to 8.3 mM was impaired in b-cells following culture with HG for 3 days, while it was preserved in ß-cells following culture with non-metabolizable L-glucose and with elevated osmolarity, insulin and ATP. This HG-induced impairment of [Ca2+]i response to 8.3 mM glucose was prevented by adding azaserine, a hexosamine pathway inhibitor, into HG culture. Conversely, culture with glucosamine, which increases the hexosamine pathway flux, impaired [Ca2+]i response to 8.3 mM glucose, mimicking HG. These results suggest that the HG-associated abnormal glucose metabolism through hexosamine pathway, but not elevated osmolarity, insulin and ATP, plays a major role in the glucotoxicity to impair the secretory function of pancreatic ß-cells.


Assuntos
Sinalização do Cálcio/efeitos dos fármacos , Glucose/metabolismo , Glucose/toxicidade , Hexosaminas/metabolismo , Células Secretoras de Insulina/efeitos dos fármacos , Células Secretoras de Insulina/metabolismo , Trifosfato de Adenosina/metabolismo , Animais , Células Cultivadas , Líquido Extracelular/efeitos dos fármacos , Líquido Extracelular/metabolismo , Hiperglicemia/metabolismo , Hiperglicemia/fisiopatologia , Insulina/metabolismo , Secreção de Insulina , Redes e Vias Metabólicas , Concentração Osmolar , Ratos , Ratos Wistar
3.
Peptides ; 23(1): 135-42, 2002 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-11814628

RESUMO

The present study examined whether a sustained increase in cytosolic Ca(2+) concentration ([Ca(2+)](i)) causes glucose-insensitivity in beta-cells and whether it could be modulated by pituitary adenylate cyclase-activating polypeptide (PACAP), a pancreatic insulinotropin. Rat single beta-cells were cultured for 2 days with sustained increases in [Ca(2+)](i), followed by determination of the [Ca(2+)](i) response to glucose (8.3 mM) as monitored with fura-2. High K(+) (25 mM) produced sustained increases in [Ca(2+)](i) in beta-cells, which were inhibited by nifedipine, a Ca(2+) channel blocker. After culture with high K(+), the incidence and amplitude of [Ca(2+)](i) responses to glucose were markedly reduced. This glucose-insensitivity was prevented by the presence of nifedipine or PACAP-38 (10(-13) M and 10-9) M) in high K(+) culture. PACAP-38 attenuated high K(+)-induced [Ca(2+)](i) increases. In conclusion, sustained increases in [Ca(2+)](i) induce glucose-insensitivity (Ca(2+) toxicity in beta-cells) and it is prevented by PACAP possibly in part due to its Ca(2+)-reducing capacity.


Assuntos
Cálcio/metabolismo , Glucose/farmacologia , Ilhotas Pancreáticas/metabolismo , Neuropeptídeos/farmacologia , Animais , Células Cultivadas , Corantes/farmacologia , Relação Dose-Resposta a Droga , Corantes Fluorescentes/farmacologia , Fura-2/farmacologia , Glucose/metabolismo , Polipeptídeo Hipofisário Ativador de Adenilato Ciclase , Potássio/metabolismo , Ratos , Fatores de Tempo , Vasodilatadores/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA